The recent FDA approval of Zepbound as a treatment for obstructive sleep apnea marks a significant advancement in therapy, primarily benefiting those who are overweight.
In the trial, tirzepatide participants showed a remarkable 63% reduction in restricted breathing, translating to an average of 30 fewer sleep interruptions nightly.
This unique pharmacologic approach illustrates that by promoting weight loss, Zepbound not only tackles obesity but effectively aids in treating obstructive sleep apnea.
The findings suggest that reducing fat tissue can effectively alleviate airway obstructions, validating our hypothesis on the link between weight and sleep apnea.
Collection
[
|
...
]